Rybelsus, the first oral GLP-1 receptor agonist approved for diabetes management, has garnered attention for its unique approach to glucose regulation. By mimicking the natural incretin hormones, this medication actively promotes insulin secretion in response to elevated blood sugar levels. Rybelsus achieves this by binding to GLP-1 receptors in the…